- Home
- CNEY vs AEON Comparison
CNEY vs AEON Comparison
Compare CNEY & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | AEON |
|---|---|---|
| Founded | 2018 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | AEON |
|---|---|---|
| Price | $0.60 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 1.9M | 210.6K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,049,275.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.38 |
| 52 Week High | $12.23 | $64.80 |
Technical Indicators
Market Signals| Indicator | CNEY | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 13.40 | 50.05 |
| Support Level | $0.71 | $0.72 |
| Resistance Level | $1.50 | $0.79 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 2.52 | 74.20 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.